Document is current

Article History

Received: 4 November 2022

Accepted: 21 December 2022

First Online: 28 December 2022

Declarations

:

: This study utilizes a centralized IRB through WCG IRB. The study protocol and centralized IRB conclusion will be reviewed and adopted by each site’s relevant local IRB prior to participation. All volunteers require written informed consent to participate.

: Consent for publication was sought and approved by all listed authors. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for the protection of human subjects as prescribed in AR 70–25.

: The authors report the following outside financial activities: TPL: AbbVie (consultant), BioFire Diagnostics (grant/research support), Cidara (advisor/consultant), Entasis (grant/research support), Ferring (advisor/consultant/speaker), Genentech (consultant), ICPD (consultant), Johnson and Johnson (consultant), Melinta (advisor/consultant), Merck (advisor/consultant, grant/research support), Paratek (advisor/consultant), Roche (consultant), Shionogi (advisor/consultant/speaker), Spero (advisor/consultant), Wockhardt (grant/research support), and Venatrox (advisor/consultant). RP reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire; is a consultant to Curetis, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, Qvella, Netflix, Abbott Laboratories, and CARB-X; has research supported by Adaptive Phage Therapeutics; has a relationship with Pathogenomix; and has a patent for Bordetella pertussis/parapertussis PCR, for a device/method for sonication with royalties paid by Samsung, and for an antibiofilm substance. Adaptive Phage Therapeutics has a nonexclusive Biological Material License agreement with WRAIR for its therapeutic phages. VGF reports personal fees from Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics, C3J, Armata, Valanbio, Akagera, Aridis, and Roche; grants from MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck, Medical Biosurfaces, Locus, Affinergy, Contrafect, Karius, Genentech, Regeneron, Deep Blue, Basilea, and Janssen; stock options from Valanbio and ArcBio; and a patent in sepsis diagnostics pending. RTS serves as a consultant or a member of Data Monitoring Committees for LyseNtech, Glaxo SmithKline, Pfizer, Merck, VIR, Sempra Energy, and SNIPR Biome. All other authors have nothing to disclose.